{"entity":{"id":"nct05261269","kind":"trial","name":"A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer","aka":[],"tldr":"A phase 1 trial of DAN-222 run by Dantari, Inc., completed.","summary":"A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer is a phase 1 interventional study registered as NCT05261269 by Dantari, Inc., with 30 participants enrolled, started 2022-02-02. Conditions recorded: HER2-negative Metastatic Breast Cancer. Interventions recorded: DAN-222 and Niraparib.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05261269","url":"https://clinicaltrials.gov/study/NCT05261269"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["dan-222"],"companies":["dantari"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05261269","phase":"1","setting":"A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer","sponsor":"Dantari, Inc.","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05261269/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"dan-222","kind":"drug","name":"DAN-222","route":"/drugs/dan-222/"}],"company":[{"id":"dantari","kind":"company","name":"Dantari","route":"/companies/dantari/"}]}}